Spyre Therapeutics, Inc.SYRENASDAQ
LOADING
|||
Net Income Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year net income growth rate
Latest
69.54%
↑ 315% above average
Average (39q)
-32.28%
Historical baseline
Range
High:81.52%
Low:-1078.38%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 69.54% |
| Q2 2025 | 17.99% |
| Q1 2025 | 20.47% |
| Q4 2024 | 18.44% |
| Q3 2024 | -77.74% |
| Q2 2024 | 11.45% |
| Q1 2024 | 30.58% |
| Q4 2023 | -57.53% |
| Q3 2023 | 81.52% |
| Q2 2023 | -1078.38% |
| Q1 2023 | 2.13% |
| Q4 2022 | -3.22% |
| Q3 2022 | 18.32% |
| Q2 2022 | 8.65% |
| Q1 2022 | -19.51% |
| Q4 2021 | -0.68% |
| Q3 2021 | -197.32% |
| Q2 2021 | 62.51% |
| Q1 2021 | 19.79% |
| Q4 2020 | -25.96% |
| Q3 2020 | 15.80% |
| Q2 2020 | -14.36% |
| Q1 2020 | 12.87% |
| Q4 2019 | 0.36% |
| Q3 2019 | -19.72% |
| Q2 2019 | -4.96% |
| Q1 2019 | -15.23% |
| Q4 2018 | -25.01% |
| Q3 2018 | -26.59% |
| Q2 2018 | -15.95% |
| Q1 2018 | -25.24% |
| Q4 2017 | 17.67% |
| Q3 2017 | -18.73% |
| Q2 2017 | -6.16% |
| Q1 2017 | -13.93% |
| Q4 2016 | 12.10% |
| Q3 2016 | -14.88% |
| Q2 2016 | -19.42% |
| Q1 2016 | -14.05% |
| Q4 2015 | -16.82% |